盖诺联合顺铂对晚期乳腺癌治疗体会  

Treatment experience of vinorelbine tartrate combined with cisplatin in the treatment of advanced breast cancer

作　　者：罗盘 肖佳 方建龙 周强 Luo Pan;Xiao Jia;Fang Jianlong;Zhou Qiang(Yueyang First People's Hospital Oncology,Yueyang,Hunan 414000)

机构地区：[1]岳阳市一人民医院肿瘤科,湖南岳阳414000

出　　处：《中国社区医师》2021年第9期45-46,共2页Chinese Community Doctors

摘　　要：目的:分析盖诺联合顺铂治疗晚期乳腺癌的临床效果。方法:2019年4月-2020年1月收治晚期乳腺癌患者64例,随机分为两组,各32例。对照组给予多西他赛联合顺铂治疗,观察组给予盖诺联合顺铂治疗,比较两组治疗效果。结果:观察组治疗总有效率及生存率均高于对照组,且不良反应发生率低于对照组,差异有统计学意义(P<0.05);观察组治疗后糖类抗原125(CA125)、癌胚抗原(CEA)、胰岛素样生长因子-1(IGF-1)等指标水平均显著低于对照组,差异有统计学意义(P<0.05)。结论:临床可采用盖诺联合顺铂治疗晚期乳腺癌,患者近期疗效理想,生存率得到提高,抗肿瘤效果理想。Objective:To analyze the clinical effect of vinorelbine tartrate combined with cisplatin in the treatment of advanced breast cancer.Methods:From April 2019 to January 2020,64 cases of patients with advanced breast cancer were enrolled,they were randomly divided into two groups with 32 cases in each group.The control group was treated with docetaxel and cisplatin.The observation group was treated with vinorelbine tartrate combined with cisplatin.The therapeutic effects between the two groups was compared.Results:The total effective rate of treatment and survival rate in the observation group were higher than those in the control group,while the incidence of adverse reactions was lower than that of control group,the differences were statistically significant(P<0.05).The levels of carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)and insulin-like growth factor-1(IGF-1)in the observation group were significantly lower than those in the control group after treatment,the differences were statistically significant(P<0.05).Conclusion:Vinorelbine tartrate combined with cisplatin can be used in the clinical treatment of advanced breast cancer,after treatment,the short-term curative effect is ideal,the survival rate is improved and the anti-tumor effect is ideal.

关 键 词：晚期乳腺癌 盖诺 顺铂 疗效 

分 类 号：R737.9[医药卫生—肿瘤]